Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort

MLA

Riveiro-Barciela, M., et al. Sofosbuvir/Ledipasvir plus Ribavirin Achieves High SVR12 in Genotype‐3 Patients with Compensated Cirrhosis and Similar to Sofosbuvir plus Daclatasvir: A Multicentre Real Life Cohort. Jan. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..69bf236113cc1805abf93458f3348f49&authtype=sso&custid=ns315887.

APA

Riveiro-Barciela, M., Alonso, S., Fernández, I., Rincón, D., Real, Y., Crespo, J., Gea, F., Olveira, A., Calleja, J. L., Polo-Lorduy, B., Carrión, J. A., Arenas, J., Devesa, M. J., Baliellas, C., Castro-Iglesias, Á., Romero-Gómez, M., Granados, R., Pascasio, J. M., Forns, X., … Fernández-Rodríguez, C. M. (2016). Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort.

Chicago

Riveiro-Barciela, M., Sonia Alonso, Inmaculada Fernández, Diego Rincón, Yolanda Real, Javier Crespo, Francisco Gea, et al. 2016. “Sofosbuvir/Ledipasvir plus Ribavirin Achieves High SVR12 in Genotype‐3 Patients with Compensated Cirrhosis and Similar to Sofosbuvir plus Daclatasvir: A Multicentre Real Life Cohort,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..69bf236113cc1805abf93458f3348f49&authtype=sso&custid=ns315887.